Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 14/20 | 0.41 |
| ▸ | CD38 | P28907 | 3/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25302334 | 1.00 | EPHX1 (0.43) | EPHX1MAPTLOXL2NOS2CD38 | |
| SCHEMBL25877954 | 1.00 | EPHX1 (0.43) | EPHX1MAPTLOXL2NOS2CD38 | |
| SCHEMBL25238187 | 0.83 | EPHX1 (0.46) | EPHX1MAPTLOXL2NOS2CD38 | |
| SCHEMBL25262550 | 0.83 | EPHX1 (0.41) | EPHX1MAPTNAMPT | |
| SCHEMBL25302921 | 0.83 | EPHX1 (0.41) | EPHX1MAPTNAMPT | |
| SCHEMBL25303130 | 0.83 | EPHX1 (0.38) | EPHX1MAPTNOS2NAMPT | |
| SCHEMBL25303126 | 0.83 | EPHX1 (0.38) | EPHX1MAPTNOS2NAMPT | |
| SCHEMBL25304538 | 0.80 | EPHX2 (0.50) | LOXL2NOS2NAMPT | |
| SCHEMBL25300150 | 0.80 | EPHX1 (0.47) | EPHX1MAPTNAMPT | |
| SCHEMBL25300149 | 0.80 | EPHX1 (0.47) | EPHX1MAPTNAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240336571-A1 | NOVEL CYCLOPROPYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2024-10-10 | — | — | US | claimed |
| EP-4452944-A1 | CYCLOPROPYL COMPOUNDS | Icagen, LLC (US) | 2024-10-30 | — | — | EP | disclosed |
| US-20240336571-A1 | NOVEL CYCLOPROPYL COMPOUNDS | ANGELINI PHARMA S.P.A. (IT) | 2024-10-10 | — | — | US | disclosed |
| WO-2023121992-A1 | CYCLOPROPYL COMPOUNDS | ICAGEN, LLC (US) | 2023-06-29 | — | — | WO | disclosed |
| WO-2023121992-A1 | CYCLOPROPYL COMPOUNDS | ICAGEN, LLC (US) | 2023-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240336571-A1 | NOVEL CYCLOPROPYL COMPOUNDS | C1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CNR1 | EPHX1 1252/4885MAPT 2445/4885LOXL2 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.